183 related articles for article (PubMed ID: 30017881)
1. The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Na
Hossain MM; Weig B; Reuhl K; Gearing M; Wu LJ; Richardson JR
Exp Neurol; 2018 Oct; 308():111-119. PubMed ID: 30017881
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Yokoyama H; Yano R; Kuroiwa H; Tsukada T; Uchida H; Kato H; Kasahara J; Araki T
Metab Brain Dis; 2010 Jun; 25(2):135-43. PubMed ID: 20424905
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice.
Yokoyama H; Yano R; Kuroiwa H; Tsukada T; Uchida H; Kato H; Kasahara J; Araki T
Metab Brain Dis; 2010 Sep; 25(3):305-13. PubMed ID: 20957419
[TBL] [Abstract][Full Text] [Related]
4. The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson's disease.
Rabaneda-Lombarte N; Serratosa J; Bové J; Vila M; Saura J; Solà C
J Neuroinflammation; 2021 Apr; 18(1):88. PubMed ID: 33823877
[TBL] [Abstract][Full Text] [Related]
5. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Sano H; Murata M; Nambu A
J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
[TBL] [Abstract][Full Text] [Related]
6. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
[TBL] [Abstract][Full Text] [Related]
7. Taurine improves neuron injuries and cognitive impairment in a mouse Parkinson's disease model through inhibition of microglial activation.
Wang K; Shi Y; Liu W; Liu S; Sun MZ
Neurotoxicology; 2021 Mar; 83():129-136. PubMed ID: 33450328
[TBL] [Abstract][Full Text] [Related]
8. Phloretin attenuates behavior deficits and neuroinflammatory response in MPTP induced Parkinson's disease in mice.
Zhang G; Yang G; Liu J
Life Sci; 2019 Sep; 232():116600. PubMed ID: 31251998
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson's disease.
Yao L; Ye Y; Mao H; Lu F; He X; Lu G; Zhang S
J Neuroinflammation; 2018 Jan; 15(1):13. PubMed ID: 29329581
[TBL] [Abstract][Full Text] [Related]
10. Zonisamide attenuates MPTP neurotoxicity in marmosets.
Choudhury ME; Moritoyo T; Yabe H; Nishikawa N; Nagai M; Kubo M; Matsuda S; Nomoto M
J Pharmacol Sci; 2010; 114(3):298-303. PubMed ID: 20948167
[TBL] [Abstract][Full Text] [Related]
11. Anti-Inflammatory and Neuroprotective Effects of PGE
Pradhan SS; Salinas K; Garduno AC; Johansson JU; Wang Q; Manning-Bog A; Andreasson KI
J Neuroimmune Pharmacol; 2017 Jun; 12(2):292-304. PubMed ID: 27734267
[TBL] [Abstract][Full Text] [Related]
12. α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease.
Kim BW; Koppula S; Kumar H; Park JY; Kim IW; More SV; Kim IS; Han SD; Kim SK; Yoon SH; Choi DK
Neuropharmacology; 2015 Oct; 97():46-57. PubMed ID: 25983275
[TBL] [Abstract][Full Text] [Related]
13. Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease.
Son HJ; Han SH; Lee JA; Shin EJ; Hwang O
Free Radic Res; 2017 Jun; 51(6):633-645. PubMed ID: 28770670
[TBL] [Abstract][Full Text] [Related]
14. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications.
Wilms H; Zecca L; Rosenstiel P; Sievers J; Deuschl G; Lucius R
Curr Pharm Des; 2007; 13(18):1925-8. PubMed ID: 17584117
[TBL] [Abstract][Full Text] [Related]
15. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
16. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson's disease mouse model: Endothelial and microglial effects.
Burks S; Raymick J; Robinson B; Hanig J; Sarkar S
Neurosci Lett; 2019 Jun; 703():86-95. PubMed ID: 30890473
[TBL] [Abstract][Full Text] [Related]
18. Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism.
Gong J; Szego ÉM; Leonov A; Benito E; Becker S; Fischer A; Zweckstetter M; Outeiro T; Schneider A
J Neurosci; 2019 May; 39(19):3752-3769. PubMed ID: 30796158
[TBL] [Abstract][Full Text] [Related]
19. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of neuroinflammatory responses and behavioral deficits by Ligusticum officinale (Makino) Kitag in stimulated microglia and MPTP-induced mouse model of Parkinson's disease.
Kim BW; Koppula S; Park SY; Kim YS; Park PJ; Lim JH; Kim IS; Choi DK
J Ethnopharmacol; 2015 Apr; 164():388-97. PubMed ID: 25449453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
